Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at ...

Source: Cardiovascular Diabetology - October 23, 2020 Category: Cardiology Authors: Guntram Schernthaner, Naim Shehadeh, Alexander S. Ametov, Anna V. Bazarova, Fahim Ebrahimi, Peter Fasching, Andrej Jane ž, Péter Kempler, Ilze Konrāde, Nebojša M. Lalić, Boris Mankovsky, Emil Martinka, Dario Rahelić, Cristian Serafinceanu, Jan Škrh Tags: Commentary Source Type: research